Use of monoclonal antibodies in renal transplantation

Immunotherapy

Volumn 3, Issue 7, 2011, Pages 871-880

  Van Den Hoogen, Martijn W F ^a   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alemtuzumab; allograft rejection; basiliximab; daclizumab; eculizumab; induction therapy; monoclonal antibody; muromonab CD3; rituximab

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID; T LYMPHOCYTE ANTIBODY;

BLOOD GROUP ABO SYSTEM; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MORBIDITY; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; CYCLOSPORINE; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MICE; RATS; RECEPTORS, INTERLEUKIN-2;

EID: 79960498901     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.72     Document Type: Review

References (75)

1. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Engl. J. Med. 363(15), 1451-1462 (2010).
2. Wasowska BA. Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol. Res. 47(1-3), 25-44 (2010).
3. Strom TB, Kelley VE. Toward more selective therapies to block undesired immune responses. Kidney Int. 35(4), 1026-1033 (1989).
4. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N. Engl. J. Med. 313(6), 337-342 (1985).
5. Ferran C, Sheehan K, Dy M et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20(3), 509-515 (1990).
6. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76(9), 1289-1293 (2003).
7. Uslu A, Nart A. Treatment of first acute rejection episode: systematic review of level I evidence. Transplant. Proc. 43(3), 841-846 (2011).
8. Friend PJ, Hale G, Waldmann H et al. Campath-1M - prophylacticuse after kidney transplantation. A randomized controlled clinical trial. Transplantation 48(2), 248-253 (1989).
9. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath- 1H-treated kidney transplant patients. Transplantation 81(1), 81-87 (2006).
10. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin. Transplant. 18(6), 759-761 (2004).
11. Csapo Z, avides-Viveros C, Podder H, Pollard V, Kahan BD. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant. Proc. 37(5), 2032-2036 (2005).
12. Basu A, Ramkumar M, Tan HP et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant. Proc. 37(2), 923-926 (2005).
13. Clatworthy MR, Friend PJ, Calne RY et al. Alemtuzumab (Campath-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 87(7), 1092-1095 (2009).
14. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117), 1701-1702 (1998).
15. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am. J. Transplant. 5(6), 1347-1353 (2005).
16. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am. J. Transplant. 8(7), 1480-1485 (2008).
17. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immuntherapy in kidney transplantation: comparison with basiliximab induction - long-term results. Am. J. Transplant. 5(10), 2539-2548 (2005).
18. Vathsala A, Ona ET, Tan SY et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80(6), 765-774 (2005).
19. Barth RN, Janus CA, Lillesand CA et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl. Int. 19(11), 885-892 (2006).
20. Farney AC, Doares W, Rogers J et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 88(6), 810-819 (2009).
21. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 83(11), 1509-1512 (2007).
22. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin. Transplant. 22(2), 200-210 (2008).
23. Ciancio G, Gaynor JJ, Roth D et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant. Proc. 42(9), 3503-3506 (2010).
24. van Gelder T, Zietse R, Mulder AH et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 60(3), 248-252 (1995).
25. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350(9086), 1193-1198 (1997).
26. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 67(2), 276-284 (1999).
27. Ponticelli C, Yussim A, Cambi V et al. Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine. Transplant. Proc. 33(1-2), 1009-1010 (2001).
28. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338(3), 161-165 (1998).
29. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67(1), 110-115 (1999).
30. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326(7393), 789-791 (2003).
31. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331(7520), 810 (2005).
32. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am. J. Transplant. 2(6), 568-573 (2002).
33. Webb NJ, Prokurat S, Vondrak K et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr. Nephrol. 24(1), 177-182 (2009).
34. Webster AC, Ruster LP, McGee R et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev.(1), CD003897 (2010).
35. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355(19), 1967-1977 (2006).
36. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N. Engl. J. Med. 359(16), 1736-1738 (2008).
37. Noel C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J. Am. Soc. Nephrol. 20(6), 1385-1392 (2009).
38. ter Meulen CG, van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor a therapy: a prospective, randomized, multicenter study. Am. J. Transplant. 4(5), 803-810 (2004).
39. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79(7), 807-814 (2005).
40. Vondran FW, Timrott K, Tross J et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl. Int. 23(5), 514-523 (2010).
41. +CD25+ regulatory T-cell pool is present in renal transplant recipients. Am. J. Transplant. 7(1), 249-255 (2007).
42. Wang Z, Shi BY, Qian YY, Cai M, Wang Q. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin. Exp. Immunol. 155(3), 496-503 (2009).
43. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(Suppl. 3), S1-S155 (2009).
44. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am. J. Transplant. 7(5 Pt 2), 1359-1375 (2007).
45. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Ra chain blockade. Transplantation 72(10), 1709-1710 (2001).
46. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am. J. Transplant. 5(1), 145-148 (2005).
47. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85(12), 1745-1754 (2008).
48. Crew RJ, Ratner LE. ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr. Opin. Organ Transplant. 15(4), 526-530 (2010).
49. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359(3), 242-251 (2008).
50. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89(9), 1095-1102 (2010).
51. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349(2), 125-138 (2003).
52. + infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am. J. Transplant. 5(9), 2248-2252 (2005).
53. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 87(12), 1837-1841 (2009).
54. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. 4(6), 996-1001 (2004).
55. Steinmetz OM, Lange-Husken F, Turner JE et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 84(7), 842-850 (2007).
56. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83(9), 1277-1280 (2007).
57. Tyden G, Genberg H, Tollemar J et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 87(9), 1325-1329 (2009).
58. Clatworthy MR, Watson CJ, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360(25), 2683-2685 (2009).
59. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin. J. Am. Soc. Nephrol. 5(12), 2363-2372 (2010).
60. Parker A, Bowles K, Bradley JA et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br. . Haematol. 149(5), 693-705 (2010).
61. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am. J. Transplant. 6(10), 2418-2428 (2006).
62. Scemla A, Loupy A, Candon S et al. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 90(11), 1180-1184 (2010).
63. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89(5), 308-318 (2010).
64. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355(12), 1233-1243 (2006).
65. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 9(1), 231-235 (2009).
66. Zuber J, Le QM, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat. Rev. Nephrol. 7(1), 23-35 (2011).
67. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am. J. Transplant. 9(11), 2644-2645 (2009).
68. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89(7), 903-904 (2010).
69. Vincenti F, Mendez R, Pescovitz M et al. A Phase I/II randomized open-label multicenter trial of efalizumab, a hmanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 7(7), 1770-1777 (2007).
70. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47 (2010).
71. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5), 391-397 (2004).
72. Patel NS, Chatterjee PK, Di Paola R et al. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J. Pharmacol. Exp. Ther. 312(3), 1170-1178 (2005).
73. de Vries DK, Lindeman JH, Tsikas D et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am. J. Transplant. 9(7), 1574-1584 (2009).
74. Vincenti F, Kirk AD. What's next in the pipeline. Am. J. Transplant. 8(10), 1972-1981 (2008).
75. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23(9), 1073-1078 (2005).